Alzheimer’s disease (AD) is a widespread
neurodegenerative disorder, causing cognitive decline and memory impairment. It affects millions globally, posing significant challenges to patients and healthcare systems. This review aims to assess the effectiveness of two commonly prescribed medications, memantine (an NMDAR blocker) and donepezil (a cholinesterase inhibitor), in managing AD.
The review encompasses clinical trials
and comparative analyses, scrutinizing the benefits
and limitations of memantine and donepezil. Studies
considered cognitive and functional outcomes,
providing insights into the therapeutic effects of these
medications. Additionally, the analysis explores the
potential synergistic effects of combining memantine
and donepezil, shedding light on their combined
efficacy.
Both memantine and donepezil demonstrate
efficacy in improving cognitive and functional aspects
in AD patients. However, the review indicates that the
combination therapy of these drugs does not exhibit
superior efficacy compared to individual use. Long-
term effects and adverse reactions necessitate further
investigation, especially with the introduction of newer
treatments like monoclonal antibodies, which adds
complexity to the landscape of AD management.
Informed decisions regarding the usage of memantine and donepezil in AD
treatment should carefully weigh potential benefits against risks for individual patients. The
review emphasizes the need for continuous research to explore both existing and evolving
therapies, aiming to enhance the quality of life for those affected by this devastating disease.
As treatment options evolve, maintaining an updated understanding of the landscape is
crucial for healthcare practitioners and researchers alike.
